Clovis Oncology (CLVS) Receives ‘Analyst’ Rating

Clovis Oncology (CLVS) : 3 brokerage houses believe that Clovis Oncology (CLVS) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Clovis Oncology (CLVS). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 6 Wall Street Analysts endorse the stock as a Buy with a rating of 2.

Clovis Oncology (CLVS) : The highest level Clovis Oncology (CLVS) is projected to reach is $30 for the short term and the lowest estimate is at $14. The consolidated price target from 6 rating analysts who initiate coverage on the stock is $24.83 and the possibility the share price can swing is $6.46.


Also, Equity analysts at the Brokerage firm SunTrust Robinson Humphrey maintains its rating on Clovis Oncology (NASDAQ:CLVS). The rating major has initiated the coverage with buy rating on the shares. The Analysts at SunTrust Robinson Humphrey raises the price target from $25 per share to $30 per share. The rating by the firm was issued on August 24, 2016.

Clovis Oncology (NASDAQ:CLVS): After opening at $29.29, the stock dipped to an intraday low of $29 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $30.67 and the buying power remained strong till the end. The stock closed at $30.63 for the day, a gain of 5.26% for the day session. The total traded volume was 3,169,507. The stocks close on the previous trading day was $29.1.

Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.